Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Biotechnology Industry
Dec 04, 2008 04:10 PM
- Analyst Comments: United Thera, Genta, Visteon, Watsco, Autonation, National Semi, Saks, Lehman, Joy Global, Nuvelo, 3D Systems, Suntech Power, Dassault, Cell Therapeutics, Analog Devices, Energy Transfer, General Growth
Aug 20, 2008 04:03 PM
- Analyst Comments: Agco, AXA Group, SID, Genta, DPL,
Jul 31, 2008 07:00 AM
- Ten Hot Stocks
Jul 08, 2008 12:21 PM
- Ten Stocks To Consider Short Selling
Jul 03, 2008 11:48 AM
- Biotech to Outperform in Down Market
Apr 21, 2008 06:20 PM
- Analyst Comments: Carnival plc, RAIT Financial Trust, Cleveland BioLabs, Cadence Design Systems, Genta, Incorporated
Mar 25, 2008 10:51 AM
- Earnings Summary: Wednesday, March 12, 2008
Mar 13, 2008 02:18 AM
- Analyst Comments: ArthroCare, Genta, Advanced Micro Devices, Genentech, Sonic Innovations, Shire Pharma, Neurochem
Feb 25, 2008 10:43 AM
- Analyst Comments: Genta, XenoPort, Theravance, Palm,
Feb 20, 2008 04:07 AM
- Tesetaxel, a Leading Oral Taxane in Clinical Development, Receives FDA Designation as an Orphan Drug for Treatment of Patients with Advanced Melanoma
Dec 04, 2008 08:20 AM
- Genta Receives Complete Response Letter from FDA to Amended Application of Genasense® in Patients with Chronic Lymphocytic Leukemia
Dec 02, 2008 05:16 PM
- Genta Incorporated Announces Third Quarter 2008 Financial Results and Corporate Highlights
Nov 06, 2008 07:18 AM
- Genta Incorporated to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Nov 03, 2008 08:44 AM
- Genta Incorporated to Host Conference Call to Discuss Third Quarter Highlights and Financial Results
Oct 30, 2008 08:19 AM
- Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Oct 06, 2008 08:36 AM
- Genta Announces Webcast of 2008 Annual Shareholders Meeting
Oct 02, 2008 08:18 AM
- Zacks Analyst Blog Highlights: Jabil Circuit, Inc., Inc., Dean Foods Co., 3Com Corp., Genta Inc. And Aracruz Celulose S.A.
Sep 30, 2008 05:16 PM
- Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
Sep 15, 2008 08:09 AM
- Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
Aug 07, 2008 07:01 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
GNTA
|
Compare to S&P
|
| YTD |
-66.35 %
|
-0.01 %
|
| 4 Weeks |
-51.39 %
|
-46.81 %
|
| 12 Weeks |
-37.50 %
|
-11.57 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 96.43 %
|
|
EPS Growth in Last Year: 96.00 %
|
|
Sales Growth in Last Quarter: -12.21 %
|
|
Sales Growth in Last Quarter: 0.00 %
|
|
|
